ADIPOQ and obesity due to melanocortin 4 receptor deficiency: These observations provide a stimulating background to the challenging hypothesis that ADPN and/or its receptors could be a potential therapeutic tool in the treatment of obesity (Li et al., 2017) and eating disorders and, certainly, this issue deserves further investigation in a translational perspective.